Patents by Inventor Erik J. Verner

Erik J. Verner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SYNTHESIS OF A BRUTON'S TYROSINE KINASE INHIBITOR
    Publication number: 20240158400
    Abstract: Described herein is the synthesis of Bruton's tyrosine kinase (Btk) inhibitor 1-(R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl) piperidin-1-yl)prop-2-en-1-one.
    Type: Application
    Filed: June 14, 2023
    Publication date: May 16, 2024
    Inventors: Cyril Ben Haim, Wei Chen, Erick Goldman, Andras Horvath, Philip Pye, Mark S. Smyth, Erik J. Verner
  • Inhibitors of Bruton's Tyrosine Kinase
    Publication number: 20220213106
    Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.
    Type: Application
    Filed: August 16, 2021
    Publication date: July 7, 2022
    Inventors: Joseph J. Buggy, Wei Chen, Lee Honigberg, David J. Loury, Zhengying Pan, Erik J. Verner
  • SYNTHESIS OF A BRUTON'S TYROSINE KINASE INHIBITOR
    Publication number: 20220098200
    Abstract: Described herein is the synthesis of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one.
    Type: Application
    Filed: February 17, 2021
    Publication date: March 31, 2022
    Inventors: Cyril Ben Haim, Wei Chen, Erick Goldman, Andras Horvath, Philip Pye, Mark S. Smyth, Erik J. Verner
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20220008424
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: February 19, 2021
    Publication date: January 13, 2022
    Inventors: Lee Honigberg, Erik J. Verner, Zhengying Pan
  • SYNTHESIS OF A BRUTON'S TYROSINE KINASE INHIBITOR
    Publication number: 20200347064
    Abstract: Described herein is the synthesis of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one.
    Type: Application
    Filed: December 4, 2019
    Publication date: November 5, 2020
    Inventors: Cyril Ben Haim, Wei Chen, Erick Goldman, Andras Horvath, Philip Pye, Mark S. Smyth, Erik J. Verner
  • INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS
    Publication number: 20200289515
    Abstract: Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.
    Type: Application
    Filed: March 21, 2019
    Publication date: September 17, 2020
    Inventors: Lee Honigberg, Erik J. Verner, Joseph J. Buggy, David J. Loury, Wei Chen
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20200108072
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: May 20, 2019
    Publication date: April 9, 2020
    Inventors: Lee Honigberg, Erik J. Verner, Zhengying Pan
  • INHIBITORS OF BRUTONS TYROSINE KINASE
    Publication number: 20200055859
    Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.
    Type: Application
    Filed: March 22, 2019
    Publication date: February 20, 2020
    Inventors: Joseph J. Buggy, Wei Chen, Lee Honigberg, David J. Loury, Zhengying Pan, Erik J. Verner
  • SYNTHESIS OF A BRUTON'S TYROSINE KINASE INHIBITOR
    Publication number: 20190367518
    Abstract: Described herein is the synthesis of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one.
    Type: Application
    Filed: December 18, 2018
    Publication date: December 5, 2019
    Inventors: Cyril Ben Haim, Wei Chen, Erick Goldman, Andras Horvath, Philip Pye, Mark S. Smyth, Erik J. Verner
  • FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF
    Publication number: 20190184196
    Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
    Type: Application
    Filed: October 18, 2018
    Publication date: June 20, 2019
    Inventors: David J. Loury, Joseph J. Buggy, Tarak D. Mody, Erik J. Verner, Norbert Purro, Sriram Balasubramanian
  • Formulations of histone deacetylase inhibitor and uses thereof
    Patent number: 10105552
    Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: October 23, 2018
    Assignee: Pharmacyclics LLC
    Inventors: David J. Loury, Joseph J. Buggy, Tarak D. Mody, Erik J. Verner, Norbert Purro, Sriram Balasubramanian
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20180085372
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: May 8, 2017
    Publication date: March 29, 2018
    Inventors: LEE HONIGBERG, Erik J. Verner, Zhengying Pan
  • SYNTHESIS OF A BRUTON?S TYROSINE KINASE INHIBITOR
    Publication number: 20180009814
    Abstract: Described herein is the synthesis of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo [3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one.
    Type: Application
    Filed: January 14, 2016
    Publication date: January 11, 2018
    Applicants: Pharmacyclics LLC, Janssen Pharmaceutica NV
    Inventors: Cyril Benhaim, Wei Chen, Erick Goldman, Andras Horvath, Philip Pye, Mark S. Smyth, Erik J. Verner
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20170362246
    Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.
    Type: Application
    Filed: August 31, 2017
    Publication date: December 21, 2017
    Inventors: Joseph J. Buggy, Wei Chen, Lee Honigberg, David J. Loury, Zhengying Pan, Erik J. Verner
  • FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF
    Publication number: 20170333731
    Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
    Type: Application
    Filed: December 21, 2016
    Publication date: November 23, 2017
    Inventors: David J. Loury, Joseph J. Buggy, Tarak D. Mody, Erik J. Verner, Norbert Purro, Sriram Balasubramanian
  • Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors
    Publication number: 20170246169
    Abstract: Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.
    Type: Application
    Filed: October 13, 2016
    Publication date: August 31, 2017
    Inventors: Lee Honigberg, Erik J. Verner, Joseph J. Buggy, David J. Loury, Wei Chen
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20170007611
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: February 12, 2016
    Publication date: January 12, 2017
    Inventors: Lee Honigberg, Erik J. Verner, Zhengying Pan
  • Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
    Patent number: 9492423
    Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: November 15, 2016
    Assignee: PHARMACYCLICS LLC
    Inventors: David J. Loury, Joseph J. Buggy, Tarak D. Mody, Erik J. Verner, Norbert Purro, Sriram Balasubramanian, Ioana Kloos, Stephane Depil
  • Formulations of histone deacetylase inhibitor and uses therof
    Patent number: 9403032
    Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: August 2, 2016
    Assignee: Pharmacyclics LLC
    Inventors: David J. Loury, Joseph J. Buggy, Tarak D. Mody, Erik J. Verner, Norbert Purro, Sriram Balasubramanian
  • Hydroxamates as therapeutic agents
    Patent number: 9186347
    Abstract: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: November 17, 2015
    Assignee: PHARMACYCLICS LLC
    Inventors: Erik J. Verner, Martin Sendzik, Chitra Baskaran, Joseph J. Buggy, James Robinson